<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/222437-a-pyrimidinedione-homocarbocyclic-compound by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 08:31:12 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 222437:&quot;A PYRIMIDINEDIONE HOMOCARBOCYCLIC COMPOUND&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;A PYRIMIDINEDIONE HOMOCARBOCYCLIC COMPOUND&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to novel compound of general formula(I) and pharmaceutically acceptable salts thereof, and pocess for the preparation of such derivatives and to pharmaceutical compositions containing the same as active ingredients. wherein R1, R2, and R3 represents independently hydrogen atom, halogen atom, C1-C10 alkyl, C1-C10 thioalkyl, C3-C8 optionally substituted cyclicalkyl, unsaturated alkyl, substituted alkyl hydroxyl or aryl hydroxyl, C1-C10 alkylamine, nitro, C1-C4 lower ester, C1.-C4 lower alkoxy, C1-C4 lower thioalkoxy; Z represents oxygen atom, sulfur atom, carbon atom and carbonyl group; X represents oxygen atom, sulfur atom; n represents an integer of 1-3; and (sub)cycloalk(en)yl represents in which R4 and R5 represents independently hydrogen atom, hydroxymethyl, protected hydroxymethyl, benzyl, substituted carbonyl, substituted alkylsulfonyl or arylsulfonyl, substituted silyl or the like.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> The present invention relates to new substituted pyrimidinedione derivatives, which are useful as an antiviral agent, treating agent for acquired immunodeficiency syndromes (AIDS), and pharmaceutically acceptable salts thereof. The invention also relates to process for the preparation of such derivatives and to pharmaceutical compositions containing the same as active ingredients.<br>
Nowadays, various compounds such as AZT, DDC, DDI and D4T have been used as chemotherapeutic agents of AIDS and have a medical action mechanism with inhibition of the replication of AIDS virus. They also have drug tolerance and undesirable side effects due to their toxicity.<br>
1. In order to overcome these problems, intensive researches have been carried out to develope antiviral chemotherapeutic agents with strong activity and with lower toxicity. Among them, researches have been focused on pyrimidine 6-substituted necleoside compounds. But, N-l substituted homocarbocyclic nucleoside derivatives were not developed as yet.<br>
The present inventors carried out an intensive research on the N-l substituted homocarbocyclic necleoside derivatives and unexpectively found out the facts that the compounds have strong activity against HIVCAIDS, Acquired immunodeficiency syndromes) as well as a lower toxicity.<br>
Accordingly, the present invention relates to new pyrimidinedione derivatives, 6-substituted pyrimidinedione homocarbocyclic nucleosides which are useful as an antiviral agent for treating acquired immunodeficiency syndromes ( AIDS ), and pharmaceutically acceptable salts thereof.<br><br>
2. The present compounds have the following general formula(I).<br>
Formula Removed<br>
wherein Ri, R2, and Rs represents independently hydrogen atom, halogen atom, Ci-Cio alkyl, Ci-Cio thioalkyl, Cs-Cg optionally substituted cyclicalkyl, unsaturated alkyl, substituted alkyl hydroxyl or aryl hydroxyl, Ci-Cio alkylamine, nitro, Ci~C4 lower ester, Ci~C4 lower alkoxy, Ci~C4 lower thioalkoxy; Z represents oxygen atom, sulfur atom, carbon atom and carbonyl group; X represents oxygen atom, sulfur atom; n represents an integer of 1-3; and (sub)cycloalk(en)yl represents<br><br><br><br>
in which R4 and R5 represents independently hydrogen atom, hydroxymethyl, protected hydroxymethyl, benzyl, substituted carbonyl, substituted alkylsulfonyl or arylsulfonyl, substituted silyl or the like.<br>
C1-C10 alkyl means straight or branch alky] group such as methyl, ethyl, propyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, 2-methyl-pentyl or the like.<br>
C1-C10 thioalkyl means straight or branch thioalkyl group such as<br>
methylthio, ethylthio, propylthio, butylthio, isobutylthio, t-butylthio,<br>
pentylthio,	isopentylthio,	hexylthio,	heptylthio,	octylthio,<br>
2-methyl-pentylthio or the like.<br>
C3-C8 optionally substituted cyclic alkyl means cyclic propyl, cyclic butyl, cyclic pentyl, methyl cyclic propyl, methyl cyclic butyl, methyl cyclic pentyl or the like.<br>
C1-C4 lower ester means a carboxylic group was esterified by lower alkyl group or the like.<br>
C1-C4 lower alkoxy means methaxy, ethoxy, propyloxy, butyloxy, isobutyloxy, t-butyloxy or the like.<br>
C1-C4 lower thioalkoxy means thiomethoxy, thioethoxy, thiopropyloxy, thiobutyloxy, thioisobutyloxy, thio t-butyloxy or the like.<br>
The substituted carbonyl group means acetyl, benzoyl, substituted benzoyl or the like.<br>
The substituted alkylsulfonyl, arylsulfonyl group means<br>
methanesulfonyl,	para-toluenesulfonyl,	benzenesulfonyl,<br>
para-nitrobenzenesulfonyl or the like<br>
The substituted silyl group means trimethylsilyl, dimethylphenylsilyl, t-butyldimethylsilyl or the like.<br>
The present inventors had studied the active compound as an antiviral agent for long time. As a result, the present inventors unexpectively found out the facts that the compounds of the general forrnula(I) have excellent antiviral activity against HIV and very low toxicity.<br>
According to the present invention, there is provided a pyrimidinedione homocarbocychc compound of general Formula (I) and pharmaceutically acceptable salts formed with inorganic or organic acids<br>
(Formula Removed)<br><br>
Wherein R1, R2 and R3 represents independently hydrofhen atom, halogen, atom, C1-C10 altyl, C1-C10 thioalkyi, C3-C4optionally substituted cyclic alkyl, unsaturated aflcyl, substituted alkyl hydroxy!, aryl hydroxy!, C1-C10 alkylamine, nitro, C1-C4 lower ester, C1-C4 lower alkoxy, C1-C4 lower thioalkoxy; Z represents oxygen atom, sulfur atom, carbon atom and carbonyl group; X represents oxygen atom, sulfur atom; n represents an integer of 1-3; and (sub) cycloalk(en)yl represents<br><br>
(Formula Removed)<br>
in which <br>
(Formula Removed)<br>
represents<br>
(Formula Removed)<br><br><br><br><br>
in which R4 and R3 represents independendy hydrogen atom, hydroxymethyl, protected hydroxymethyl, benzyl, substituted carbonyl, substituted alkylsulfonyl or arylsulfonyl, substituted silyl or the like.<br>
In accordance with present invention, there are provided pharmaceutical compositions comprising one or more of the general formula(I) and their salts with a excellent antiviral activity against HIV and very low toxicity.<br>
In accordance with still another aspect of the present invention, there are provided with processes for preparing the compounds of the general formula(l) and their salts.<br>
The   compounds    of   the   present   invention    can    be   mixed   with<br>
pnarmaceutically acceptable vehicles by a known method to give pharmaceutical compositions and the pharmaceutical compositions can be used to prevent or treat various kinds of virus disease. Another object of the present invention is to provide pharmaceutical compositions containing the general formula(I) and their salts.<br><br><br>
The acids which can be reacted with the compounds of the general formula(I) to form acid salts are pharmaceutical acceptable inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid ; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, succinic acid, citric acid, maleic acid malonic acid,; sulfonic acids such as sulfonic acid, methanesulfonic acid, ethanesulfonic acid, bezenesulfonic acid, toluenesulfonic acid ; amino acids such as alanine, glycine, phenyl glycine, serin, cisserin, cystein, asparaginic acid, glutamic acid, lysine, arginine, tylosine, proline or the like. The vehicles which can be used in the preparation of pharmaceutical compositions containing the compounds of the general formula(I) as active ingredient are sweetening; agent, binding agent, dissolving agent, aids for dissolution, wetting agent, emulsifying agent, isotonic agent, adsorbent, degrading agent, antioxident, antiseptics,  lubricating agent, filler and perfume or the like such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium carboxy methyl cellulose, agar, talc, stearic' acid, magnesium stearate, calcium stearate, magnesium aluminium silicate, starch, gelatine, tragacanth gum, methyl cellulose, glycine, silica, alginic acid, sodium alginate, water, ethanoi, polyethyleneglycol, polyvinyl pyrrolidone, sodium chloride, potassium chloride, orange essence, vanila aroma or the like.<br>
Daily dosage of the compound of the general formula(I) may be varied depending on age, sex of patient and the degree of disease. Daily dosage is l.Omg to 5,000mg and may be administered one to several times.<br>
The compounds of the general formula(l) may be prepared by the following scheme 1.<br>
Scheme 1 <br><br>
(Scheme Removed)<br><br>
wherein (Sub)cycloalk(en)yl, R1, R2, R3, 2, X, and n have the same meanings as defined above and Lie represents a leaving group as a halogen atom, alkylsulfonyl or arylsulfonyl group.<br>
The compounds of the general formula (I) may be prepared by reacting a compound of the general formula(a) and the general formula (b) in the presence of a base.<br>
Representative of the base include sodium bicarbonate, sodium carbonate, potassium carbonate, sodium hydride, potassium hydride, cesium carbonate Representatives of the solvent include dirnethylformamide, ethanol, acetonitrile, dirnethylsulfoxide or the like. The reaction may be carried out between 10°C and l00°C for 5-48hrs.<br>
The compounds of the general formula(I) may be prepared by the following scheme 2.<br>
Scheme 2<br>
(Scheme Removed)<br><br>
wherein n has the same meaning and m is an integer of 0-2. The<br>
representative reducting agents include sodium borohydride, lithium<br>
aluminium hydride and the activating group of hydroxy pant include<br>
halogen atom and sulfonyl group or the like. The sulfonyl group<br>
include alkylsulfonyl group such as methanesulfonyl and arylsulfonyl<br>
group such as para-toluenesulfonyl, benzenesulfonyl and<br>
para-nitrobenzenesulfonyl  group.	The   general  formula(d)   can   be<br>
effectively obtained by the reaction of the general formula(c) and the : reduction agent. And the general forrnula(b) can be effectively prepared by   the introduction of the activating group of the general formula(c).<br>
The known compounds of 6-substituted pyrimidinedione derivatives (a) used in the preparation of the- general formula(I) are described in prior paper( WO 93/02044, WO 95/18109 ) or may be prepared in a similar method to the paper.<br>
Examples<br>
The   compounds   of   the   general   formula(I)   are   prepared   by   the following examples.<br>
(Formula Removed)<br>
wherein R1, R2, R3, Z, X,  (Sub)cycloalk(en)yl and n have the same. meanings above.<br><br><br>
l~[(Cyclopent-3-en-l-yl)methyl]-5-ethyl-6-phenylthio-2,4-pyrimidinedio ne<br>
1-a) (Cyclopent-3-en-l-yl)methyl toluenesulfonate<br>
A mixture of (cyclopent-3-en-l-yl)methanoK 1.96g, 20mmol ) and para-toluenesulfonylchloride( 3.81g, 20mmol ) were stirred at room temperature for 2hrs in pyridine( 30ml ). After the concentration of pyridine, the reaction residues were extracted with dichloromethane, washed IN HC1, dried with MgSO-i, concentrated and separated by the column chroma tography to give the desirable product ( 4.20g ).<br>
Yield(%): 83.2<br>
TH   NMRCCDCls):    8    2.11 (2H,m),   2.42(3H,s),   2.49(3H,m),   3.82(2H,d),<br>
5.67(2H,s),     7.40(2H,d),   7.65(2H,d).<br>
1-b)<br>
l-[(Cyclopent-3-en-l-yl)rnethyl]-5-ethyl-6-phenylthio-2,4-pyrirnidine-dione<br>
A mixture of 5-ethyl-6-phenylthio-2,4-pyrimidinedione( O.lOg, 0.40mmol ) and (cyclopent-3-en-lyl)methyl toluenesulfonate ( 0.12g, 0.40mmol ) in dimethylformamide( 10ml ) were heated at 90°C for overnight in the presence of sodium bicarbonate( 41mg, 0.48mmol ). After the concentration of dimethylformamide under vacuum distillation, the desirable product was obtained as white solid( 65mg ) by the separation of column chromatography.<br>
Yield(%): 49.1<br>
m.p:<br>
1H   NMR(CDC13):    8    1.13(3H,t),   2.10(2H,m),   2.38(2H,m),   2.70(2H,q),<br><br>
3.97(2H,dJ=7.65Hz),  5.67(2H,s),  7.14-7.53(5H,m), 8.51(lH,s).<br>
Example 2)<br>
l-[(Cyclopent-3-en-l-yl)methyl]-5-ethyl-6-(3,5-dimethylphenylthio)-2,4<br>
-pyrimidinedione<br>
5-ethyl-6- (3,5-dimethylphenylthio) -2,4-pyrimidinedione	and<br>
(cyclo-3-en-l   -yOmethyl  toluenesulfonate  were reacted  by  the  same way with example 1 to obtain the titled compound.<br>
Yield(%): 45.2 m.p: 128-130°C<br>
'H   NMR(CDCl3):       S    1.03(3H,t),   2.10(2H,m),   2,37(2H,m),   2.68(2H,q),<br>
2.83(lH,m),        3.99(2H,dJ=7.65Hz),    5.68(2H,s), 6.73(2H,s), 6.88(lH,s), 8.98(lH,s).<br>
Mass: m/e 356(M+), 219( 100 )<br>
Example 3)<br>
l-[(Cyclopent-3-en-l-yl)methyl]-5-isopropyl-6-phenylthio-2,4-pyrimidin<br>
edione<br>
5-Isopropyl-G-phenylthio-2,4-pyrimidinedione	and<br>
(cyclopent-3-en-l-yl)   methyl   toluenesulfonate   were   reacted   by   the same way with example 1 to obtain the titled compound.<br>
Yield(%): 57.6 m.p: 131-134°C<br>
'li   NMR(CDCl3):         d    1.21(6H,d,J=6.95Hz),    2.10(2H,m),    2.39(2H,m),<br>
2.80(lH,m),    4.06(2H,dJ=7.65Hz),    5.68(2H,s), 7.14-7,35(5H,m), 9.14(lH,s)<br><br>
Mass: m/e 342(M+), 233(100)<br>
Example 4)<br>
l-[(Cyclopent-3-en-l-yl)methyl]-5-isopropyl-6-(3,5-dimethylphenylthio) -2,4 -pyrimidinedione<br>
5-Isopropyl-6- (3,5-dimethylphenylthio) -2,4-pyrimidinedione	and<br>
(cyclopent-3-en-l-yl)methyl toluenesulfonate were reacted by the same way with example 1 to obtain the titled compound.<br>
Yield(%): 62.8 m.p: 139-141°C<br>
TH    NMR(CDCb):         8     1.20(6H,dJ=6.95Hz),    2.10(2H,m),	2.28(6H,s),<br>
2.39(2H,m),          2.77(lH,m),	3.51 (lH,m),<br>
4.05(2H,dJ=7.65Hz), 5.68(2H,s),	6.74(2H,s),<br>
6.88(lH,s), 8.34(lH,s).<br>
Mass: m/e 370(M"), 233(100)<br>
Example 5)<br>
l-[(Cyclopent-l-en-l-yl)methyl]-5-ethyl-6-phenylthio-2,4-pyrimidinedi-<br>
one<br>
5-a) (Cyclopent-l-en-l-yl)methyl toluenesulfonate<br>
A mixture of (cyclopent-l-en-l-yl)methanoK 1.96g, 20mmol ) and para-toluenesulfonylchloride( 3.81g, 20mmol ) were stirred at room temperature for 2hrs in pyridine( 30ml ). After the concentration of pyridine, the reaction residues were extracted with dichloromethane, washed IN HC1, dried with MgSO4, concentrated and separated by the column chromatography to give the desirable product! 4.52g ).<br>
Yield(%): 89.6<br><br>
'IT    NMIKCDCk):     8    1.84(2H,m),    2.23(4H,s),    2.49(3H,s),    4.21(2H,s),<br>
5.27(lH,s), 7.40(2H,d), 7.65(2H,d).<br>
5-b)<br>
l-[(Cyclopent-l-en-l-yl)methyl]-5-ethyl-6-phenylthio-2,4-pyrimidine-dione<br>
A mixture of 5-ethyl-6-phenylthio-2,4-pyrimidinedione( O.lOg, 0.40mmol ) and (cyclopent-3-en-lyl)methyl toluenesulfonate( 0.12g, 0.40mmol ) in dimethylformamide( 10ml ) were heated at 90°C for overnight in the presence of sodium bicarbonate( 41mg, 0.48mmol ). After the concentration of dimethylformamide under vacuum distillation, the desirable product was obtained as white solid( 45mg ) by the separation of column chromatography.<br>
Yield(%): 34.2 m.p: 181-183°C<br>
*H   NMR(CDC13):    S    1.01(3H,t),    1.84(2H,m),   2.23(2H,m),   2.69(2H,q),<br>
4.66(2H,s),	5.26(lH,s),	7.15-7.34(5H,m),<br>
8.94(lH,s)<br>
Example 6)<br>
1 -[(4-Hydroxymethylcyclopent-l -en-1 -yDmethyl] -5-ethyl-6-phenylthio-<br>
2,4-pyrimidinedione.<br>
G~a)	(4-t-Butyldimethylsilyloxymethylcyclopent-l -en-1 -yDmethyl<br>
bromide<br>
The carbon tetrabromideC 1.39g, 4.2mmol ) and triphenylphosphine( 1.37g, 5.2mmol ) were added in dichloromethane solution of (4-t-Butyldimethylsilyloxymethylcyclopent-l-en-l-yl)methyl alcohoK 0.85g, 3.5mmol ) under ice bath and then stirred for SOmin at 0°C. The reaction mixture was stirred for overnight at room temperature,<br><br>
extracted with dichloromethane, dried with MgSO/i, filtered, concentrated and separated by column chromatography to give a desirable product ( 0.53g ).<br>
Yield(%): 49.7<br>
'II   NMRCCDCls):    8    0.05(6H,s).   0.90(9H,s),   2.18(2H,m),   2.50(3H,m),<br>
3.50(2H,dJ=6.75Hz), 4.05(2H,s), 5.71(lH,s)<br>
6-b)<br>
1 - [ (4 -My droxymethy Icyclopent-1 -en -1 -yDmethyl] -5-ethyl-6-phenylthio-2,4-pyrimidinedione<br>
A     mixture     of     5-ethyl-6-phenylthio-2,4-pyrimidinedione(     0.16g,<br>
O.GGmmol	)	and<br>
(4-t-butyldimethylsilyloxymethylcyclopent-l-en-l-yl)methyl bromide(<br>
0.20g, O.GGmmol ) in dimethylformamide( lOmmol ) were heated at 50°C<br>
for overnight in the presence of sodium bicarbonate( 66mg, 0.79mmol ).<br>
After	the	concentration	of	dimethylformamide,<br>
[(4-t-butyldimethylsilyloxymethyl	cyclo-<br>
pent-l-en-l-yl)methyl]-5-ethyl-6-phenylthio-2,4-pyrimidinedione was<br>
obtained by the separation of the column chromatography. And then,<br>
this compound in	THF( 10ml )was reacted with<br>
n-tetrabutylammoniumfluoride at room temperature for Ihr. After the concentration of THF, the residue was separated by column chromatography to give a desirable product( 35 mg ).<br>
Yield(%): 14.8 m.p: 161-163°C<br>
*H   NMR(CDC13):    S    1.01(3H,t),   2.03(2H,m),   2.38(2H,m),   2.50(lH,m),<br>
2.68(2H,q),       3.50(2H,dJ=6.65Hz),       5.23(lH,s), 7.15-7.35(5H,m), 8.62(lH,s).<br>
Example 7)<br><br>
l-[(4-Hydroxymethylcyclopent-l-en-l-yl)methyl]-5-ethyl-6-(3,5-dime-thylphenylthio)-2,4-pyrimidinedione<br>
5-Eihyl-6-(3,5-dimethylphenylthio)-2,4-pyrimidinedione	and<br>
(4-t-butyl-dimethylsilyloxymethylcyclopent-l-en-l-yl)methyl bromide were raided by the same way with the example 6 to obtain the titled compound( 48mg ).<br>
Yield(%): 21.4 m.p: 57-60°C<br>
rll   NMR(CDC13):        8    1.02(3H,t),   2.04(2H,m),   2.28(6H,s),   2.39(H,m),<br>
2.51 (lH,m), 2.68(2H,q), 3.51(2H,dJ=9.70Hz), 4.63(2H,q), 5.23(lH,s), 6.75(2H,s), 6.87(lH,s), 9.38(lH,s).<br>
Example 8)<br>
l-[(4-Hydroxymethylcyclopent-l-en-l-yl)methyl]-5-isopropyl-6-phenyl-<br>
thio-2,4-pyrimidinedione<br>
5-Isopropyl-6-phenylthio-2,4-pyrimidinedione	and<br>
[(4-t-butyIdimethylsilyl-oxymethylcyclopent-l-en-l-yl)methyl bromide were reacted by the same way with the example 6 to obtain the titled compound( 67mg )<br>
Yielcl(%): 29.5 m.p: 166-168°C<br>
*H   NMR(CDCl3):       S    1.18(3H,d),   1.19(3H,d),   2.05(2H,m),   2.41 (2H,m),<br>
2.50(lH,m),   3.49(lH,m),   3.52(2H,d),   4.70(2H,q), 5.24(lH,s), 7.16-7.34(5H,m), 8.63(lH,s).<br>
Example 9) l-[(4-IIydroxymethylcyclopent-l-en-l-yl)methyl]-5-isopropyl-6-(3,5-di<br><br>
-methy Ipheny Ithio ) - 2,4 -py rimidinedione<br>
5-Isopropy 1-6- (3,5-dimethylphenylthio) -2,4-pyrimidinedione	and<br>
(4-t-butyldimethysilyloxymethylcyclopent-l-en-l-yl)methyl bromide were reacted by the same way with the example 6 to obtain the titled compound ( 73mg )<br>
(%): 33.1 m.p: 147-148°C<br>
'II   NMR(CDCb):       S    1.20(3H,d),   1.21(3H,d),   2.05(2H,m),   2.28(6H,s),<br>
2.40(2H,d),	2.59(lH,m),	3.49(lH,m),<br>
3.52(2H,dJ=6.85Hz),   4.70(2H,q),         5.24(lH,s), 6.75(2H,s), 6.87(lH,s), 9.06(lH,s)<br>
Mass: m/e 400(M+), 263(100)<br>
Example 10)<br>
l-[(5-Iiydroxymethylcyclopent-l-en-l-yl)methyl]-5-ethyl-6-phenylthio-<br>
2,4-pyrimidinedione<br>
10-a)        (5-t-butyldimethylsilyloxymethylcyclopent-l-en-l-yl)methyl bromide<br>
The carbon tetrabromideC 8.5g, 25.7mmol ) and triphenylphosphine( 8.4g, 32.2mmol ) were added in dichloromethane solution of (5-t-Butyldimethylsilyloxymethylcyclopent-l-en-l-yl)methyl alcohoK 5.2g, 21.4mmol ) under ice bath and then stirred for 30min at 0°C. The reaction mixture was stirred for overnight at room temperature, extracted with dichloromethane, dried with MgSO4, filtered concentrated and separated by column chromatography to give a desirable product ( 3.08g ).<br>
Yield(%): 47.2<br><br>
rH   NMRCCDCls):    8    0.05(6H,s).   0.90(9H,s),   1.71 (2H,m),   2.05(2H,m),<br>
2.30(2H,m),         3.62(2H,dJ=5.80Hz),    4.15(2H,s), 5.71 (lH,s).<br>
10-b)<br>
l-[(5-Iiydroxymethylcyclopent-l-en-l-yl)methyl]-5-ethyl-6-phenylthio-2,4-pyrimidinedione<br>
A     mixture     of     5-ethyl-6-phenylthio-2,4-pyrimidinedione(     0.16g,<br>
O.GGmmol	)	and<br>
(5-t-butyldimethylsilyloxymethylcyclopent-l-en-l-yl)methyl bromide(<br>
0.20g, 0.66mmol ) in dimethylformamide( 10ml ) were heated at 50°C<br>
for overnight in the presence of sodium bicarbonate( 66mg, 0.79mmol ).<br>
After	the	concentration	of	dimethylformamide,<br>
[(5-t-butyldimethylsilyloxymethyl<br>
cyclopent-l-en-l-yl)methyl]-5-ethyl-6-phenylthio-2,4-pyrimidinedione was obtained by the separation of the column chromatography. And then, this compound in THF( 10ml ) was reacted with n-tetrabutylammoniumfluoride at room temperature for Ihr. After the concentration of THF, the residue was separated by column chromatography to give a desirable product( 35 mg ).<br>
Yield(%): 18.2 m.p: 155-156°C<br>
]H   NMR(CDCl3):       81.04(3H,t),   1.81-1.90(4H,m),   2.72(3H,m),   3.56-3.7<br>
(2H,dd,J=4.35Hz), 4.70(2H,ddJ=16.9Hz) 5.32(lH,s), 7.17-7.36(5H,m),   9.90(lH,s).<br>
Example 11)<br>
l-[(5-Hydroxymethylcyclopent-l-en-l-yl)methyl]-5-ethyl-6-(3,5-dimeth<br>
ylphenylthio)-2,4-pyrimidinedione<br>
5-Ethyl-6-(3,5-dimethylphenylthio)-2,4-pyrimidinedione	and<br>
(5-t-butyldimethylsilyloxymethylcyclopent-l-en-l-yl)methyl        bromide<br><br>
were reacted by  the  same with  the example  10  to  obtain the  titled compound.<br>
Yield(%): 22.7 m.p: 59-GO°C<br>
'II NMR(CDC13):     S   1.05(3H,t), 1.83-2.27(4H,m), 2.28(6H,s), 2.73(3H,m),<br>
3.57-3.74(2H,ddJ=4,30Hz), 4.60(2H,dd,J=17Hz), 5.31 (IH.s), 6.77(2H,s), 6.88(lH,s), 9.39(lH,s).<br>
Example 12)<br>
l-[(5-Hydroxymethylcyclopent-l-en-l-yl)methyl]-5-isopropyl-6-(3,5-di<br>
methylphenylthio)-2,4-pyrimidinedione<br>
5-Isopropyl-6-(3,5-dimethylphenylthio)-2,4-pyrimidinedione	and<br>
(5-t-butyldimethylsilyloxymethylcyclopent-l -en-1 -yDmethyl	bromide<br>
were  reacted by  the  same with  the  example  10  to  obtain	the  titled<br>
compound. ( 68mg )<br>
Yield(%): 29.9 m.p: 6G-68°C<br>
'H      NMR(CDC13):	d       1.21(3H,dJ=7.0Hz),      1.24(3H,dJ=7.0Hz),<br>
1.81-2.34(4H,m), 2.73(lH,m), 3.51 (lH,m), 3.57-3.74(2H,ddJ=4.45Hz), 4.66(2H,dd,J=17.0Hz),<br>
Example 13)<br>
1 -[ (5-Hydroxymethylcyclopent-l -en-1 -yDmethyl] -5-Isopropyl-6- (3,5~di<br>
methyl-phenylthio)-2,4-pyrimidinedione<br>
5-Isopropyl~6- (3,5-dimethylphenylthio) -2,4-pyrimidinedione	and<br>
(5-t-butyldimethylsilyloxymethylcyclopent-l-en-l-yl)methyl        bromide were reacted by the same with the example 10 to obtain the titled<br><br>
compoundC 83mg ). Yield(%): 37.6<br>
m.p: 81-82°C<br>
'II      NMR(CDC13):	8       1.22(3H,dJ=6.9Hz),      1.25(3H,dJ=6.9Hz),<br>
1.82-2.25(4H,m)	2.28(6H,s),<br>
2.74 (lH,m),	3.53(lH,m),<br>
3.55-3.77(2H,dd,	J=4.25Hz),<br>
4.70(2H,ddJ=17.0Hz),	5.32(lH,s),<br>
6.78(2H,s),     6.88(lH,s), 8.41(lH,s).<br>
Example 14)<br>
l-[(Cyclopent-3-en-l-yl)methyl]-5-ethyl-6-(3,5-dimethylphenoxy)-2,4-py ri midi nedione.<br>
5-Ethyl-6-(3,5-dimethylphenoxy)-2,4-pyrimidindione	and<br>
(cyclopent-3-en-l-yl)methyl toluenesulfonate were reacted by the same method with the example   1 to obtain the titled compound( 68mg ).<br>
Yield(%): 49.9 m.p: 179-180°C<br>
XH   NMR(CDCls):       d    1.02(3H,tJ=7.5Hz),   2.02-2.05(2H,m),   2.32(6H,s),<br>
2.34(2H,m),      2.68(3H,m),      3.66(2H,d,J=7.5Hz), 5.67(2H,s), G.50(2H,s), 6.77(lH,s), 8.92(lH,s).<br>
Mass: m/e 340(M+), 219(100)<br>
Example 15)<br>
l-[(Cyclopent-3-en-l-yl)methyl]-5-isopropyl-6-(3,5-dimethylphenoxy)-2<br>
,4-pyrimidinedione.<br>
5-Isopropyll-6-(3,5-dimethylphenoxy)-2,4-pyrimidmdione	and<br><br>
(cyclopent-3-en-l-y])methyl toluenesulfonate were reacted by the same method with the example   1 to obtain the titled compound( 73mg ).<br>
Yield(%): 51.5 m.p: 183-184°C<br>
'll    NMRCCDCb):        8     1.14(3H,s),    1.15(3H,s),    2.05(2H,ddJ=5.29Hz),<br>
22.31 (6H,s),	2.28(2H,ddJ=8.56Hz),<br>
2.73-2.83(2H,m),	3.65(2H,dJ=7.5Hz)<br>
5.67(2H,s), 6.50(2H,s), 6.77(lH,s), 8.96(lH,s).<br>
Example 16)<br>
l-[(Cyclopent-3-en-l-yl)methyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-<br>
pyrimidinedione.<br>
5-Ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidindione	and<br>
(cyclopent-3-en-l-yl)methyl toluenesulfonate were reacted by the same method with the example   1 to obtain the titled compound ( 84mg ).<br>
Yield(%): 59.6 m.p: 209-210°C<br>
]II  NMR(CDC13):       d   0.98(3H,tJ=7.5Hz),   2.02(2H,m),   2.26-2.37(2H,m),<br>
2.41 (6H,s),  2.68-2.73(3H,m),  3.82(2H,dJ=7.5Hz),<br>
5.58-5.60(2H,m),	7.34(lH,s), 8.82(lH,s).<br>
Mass: 352(M+), 219(100)<br>
Example 17)<br>
l-[(Cyclopent-3-en-l-yl)methyl]-5-isopropyl-6~(3,5-dimethylbenzoyl)-2, 4 -py ri mi dinedione.<br>
5-Isopropyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
(cyclopent-3-l-yl)methyl   toluenesulfonate   were   reacted   by   the   same<br><br>
method with the example   1 to obtain the titled compound( 81mg ). Yield(%): 55.2 m.p: 196-197°C<br>
lli      NMR(CDCb):	d       1.12(3H,dJ=7.0Hz),       1.23(3H,dJ=7.0Hz),<br>
2.01-2.03(2H,m),	2.26-2.34(3H,m),<br>
2.40(6H,s),	2.58-2.62(lH,m),<br>
3.18(111,	dd,J=7.56Hz),<br>
3.84(lH,ddJ=7.56Hz),    5.56(lH,m),    5.60 ), 7.34(lH,s), 7.51 (2H,s), 8.77(lH,s).<br>
Example 18)<br>
l-[(4-IIydroxymethylcyclopent-l-en-l-yl)methyl]-5-ethyl-6-(3,5-dimeth<br>
yl-phenoxy)-2,4-pyrimidinedione<br>
5-Ethyl-6-(3,5-dimethylphenoxy)-2,4-pyrimidinedione	and<br>
(4-t-butyldimethylsilyloxymethylcyclopent-l-en-l-yl)methyl bromide were reacted by the same method with example 6 to obtain the titled compound. ( 52mg )<br>
Yield(%): 21.3<br>
rH NMR(CDCl3):   §   0.95(3H,t,J=7.5Hz), 2.05(2H,m), 2.21(2H,q,J=10.0Hz),<br>
2.30(6H,s), 2.38-2.43(2H,m), 2.50-2.55(lH,m), 3.49(2H,dJ=5.0Hz), 4.37(2H,s), 5.35(lH,s), 6.52(2H,s), 6.77(lH,s), 8.99 (lH,s).<br>
Example 19)<br>
l-[(5-Hydroxymethylcyclopent-l-en-l-yl)methyl]-5-ethyl-6-(3,5-dime-thyphenoxy ) -2,4-pyrimidinedione<br>
5-Ethyl-6-(3,5-dimethylphenoxy)-2,4-pyrimidinedione	and<br>
(5-t-butyldimethy- lsilyloxymethylcyclopent-l-en-l-yl)methyl bromide were reacted by the same method with example 6 to obtain the titled<br><br>
compound ( 52mg ). Yield(%): 21.3 m.p: 119-120°C<br>
]II NMR(CDC13):   S 0.95(3H,t,J=7.5Hz), 1.77-1.82(lH,m), 1.98-2.04(lH,m),<br>
2.17-2.25(2H,m), 2.30(6H,s), 3.57(lH,d,J=5,OHz), 3.66(lH,dJ=5.0Hz), 3.90(2H,dJ-14.0Hz), 5.50(lH,s), 6.53(2H,s), 6.78(lH,s), 8.72(lH,s).<br>
Example 20)<br>
l~[(Cyclopentyl)methyl]-5-isopropyl-6-(3,5-dimethyphenylthio)-2,4-pyri-<br>
midinedione<br>
20-a) (Cyclopentyl)methyl toluenesulfonate<br>
To cyclopentanemethanoK 2.0g, 20mmol ) in pyridine( 30ml ) was added para-toluenesulfonyl chloride( 3.81g, 20mmol ) with stirring. After 2hrs at room temperature, the reaction mixture was concentrated for removement of pyridine, extracted with dichloromethane, dried, filtered, concentrated and separated by a column chromatography to give a desirable product! 3.80g ).<br>
Yield(%): 74.7<br>
]H    NMR(CDCls):     3     1.26-1.30(2H,m),    1.52-1.53(2H,m),    1.66(4H,m),<br>
2.09(lH,m),     2.48(3H,s), 3.74(2H,d),  7.40(2H,d), 7.72(2H,d).<br>
20-b)<br>
l-[(Cyclopentyl)methyl]-5-isopropyl-6-(3,5-dimethylphenylthio)-2,4-pyrimidinedione.<br>
A	mixture	of<br>
5~isopropyl-6- (3,5-dimethylphenylthio) -2,4-pyrimidinedione(	0. lOg,<br><br>
0.40mmol ) and cyclopentyl toluenesulfonate( O.lg, 0.4mmol ) in dimethylformamide( 10ml ) were heated at 100°C for overnight in the presence of sodium bicarbonate( 41mg, 0.48mmol ). After the concentration of dimethylformamide, the desirable product was obtained by the separation of the column chromatography to give a desirable product as a white solid ( 75mg ).<br>
Yiekl(%): 50.3 m.p: 145-146°C<br>
lli      NMR(CDCls):       8       1.20(3H,s),      1.22(3H,s),      1.26-1.30(2H,m),<br>
1.52-1.53(2H,m),     1.66(4H,m),     2.28(6H,s),<br>
2.32-2.35(lH,m),	3.48-3.54(lH,m),<br>
4.02(2H,dJ=7.5Hz),   6.74(2H,s),   6.87(lH,s), 9.27(lH,s).<br>
Mass: m/e 327(M+), 275(100)<br>
Example 21)<br>
l-(Cyclopentyl)methyl-5-isopropyl-6-(3,5-dimethylphenoxy)-2,4-pyrimi-<br>
dinedione<br>
5~Isoproyl-6-(3,5-dimethylphenoxy)-2,4-pyrimidinedione	and<br>
(cyclopentyl) methyl toluenesulfonate were reacted by the same method with example 20 to obtain the titled compound ( 53mg ).<br>
Yield(%): 37.2 m.p: 157-158°C<br>
]II      NMR(CDC13):       8       1.14(3H,s),      1.15(3H,s),      1.21-1.25(2H,m),<br>
1.53-1.55(2H,m),	1.65-1.68(4H,m),<br>
2.26-2.29(lH,m), 2.31 (6H,s), 2.78-2.83(lH,m), 3.61(2H,dJ=7.5Hz), 6.51(2H,s), 6.77(lH,s), 9.04(lH,s).<br><br>
Example 22)<br>
l-(Cyclopentyl)methyl-5-isopropyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimi-<br>
dinedione<br>
5-Isopropyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
(cyclopentyl)methyl toluenesulfonate were reacted by the same method with example 20 to obtain the titled compound ( 84mg ).<br>
Yield(%): 57.0 m.p: 167-168°C<br><br>
II         NMRCCDCh):	8<br><br>
1.12(3H,dJ=7.0Hz),<br>
1.23(3H,dJ=7.0Hz),<br>
1.46-1.47(2H,m),	1.57(4H,m),<br>
2.10-2.16(lH,m), 2,30-2,36         (lH,m),<br>
2.41 (6H,s),	3.15(lH,ddJ=7.05Hz),<br>
3.84(lH,ddJ=7.5	Hz),   7.34(lH,s),<br>
7.52(2H,s),<br><br>
Mass: m/e 368(M+), 133(100)<br>
Example 23)<br>
l-(Cyclopentyl)methyl-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidine-<br>
dione<br>
5-Ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
(cyclopentyl)-   methyl   toluenesulfonate   were   reacted   by   the   same method with example 20 to obtain the titled compound. ( 80mg )<br>
Yieid(%): 56.4<br>
m.p: 186-187°C<br>
1H        NMR(CDCla):         8        0.94(3H,tJ=7.5Hz),        1.24(3H,dJ=7.0Hz),<br><br>
1.46-1.47(2H,m),	1.56-1.58(4H,m),<br>
2.14(lli,m), 2.41 (6H,s), 2.62(2H,q,), 3.18(lH,dJ=7.0Hz), 3.84(lH,dJ=7.0Hz), 7.34(lli,s), 7.51 (2H,s), 8.94(lH,s).<br>
Example 24)<br>
l-{[4-Bis(hydroxymethyl)cyclopent-l-en-l-yl]methyl}-5-ethyl-6-phenyl<br>
-thio-2,4-pyrimidinedione<br>
24-a)	[4-Bis(t-butyldimethylsilyloxylmethyl)cyclopent-l-en-l-yl]<br>
methyl	bromide<br>
A    mixture    of    carbon    tetrabromide(     1.99g,    G.Ommol     )     and triphenylphosphine(        1.97g,       7.5mmol       )        were       added       to [4- bis (t-butyldimethylsilyloxymethyl)cyclopent-l -en-1 -yljmethyl alcohol ( 1.93g, S.Ommol ) in dichloromethane under ice bath and then, the reaction mixture was stirred for 30min at 0°C.       After overnight at room temperature, the reaction mixture was extracted with dichloromethane, dried with MgSO4, filtered, concentrated and separated by column chromatography to give a desirable product( 1.43g ).<br>
Yiekl(%): 63.5<br>
1H NMlKCDCb):      d   0.05(6H,s), 0.90(9H,s),  2.09(2H,br),  2.15(2H, br),<br>
3.64(4H,m), 4.04(2H,s), 5.21 (lH,s).<br>
24-b)<br>
l-{[4-Bis(hydroxymethyl)cyclopent-l-en-l-yl]methyl}-5-ethyl-6-phenylthio-2,4-pyrimidinedione<br>
A    mixture    of    5-ethyl-6-phenylthio-2,4-pyrimidinedione(    0.16g,<br>
O.GGmmol	)	and<br>
[4-bis(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl)methyl<br>
bromideC 0.30g, 0.66mmol ) in dimethylformamide( 10ml ) were heated<br>
at 50°C  for overnight in the presence of sodium bicarbonateC  66mg,<br>
0.79mmol     ).	After    the     concentration     of     dimethylformamide,<br><br>
l-{[4-bis(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl)methyl}-5-ethyl-G-phenylthio-2,4-pyrimidinedione was obtained by the separation of the column chromatography. And then, this compound in THF( 10ml ) was reacted with n-tetrabutylammoniumfluroride at room temperature for Ihr. After the concentration of THF, the residue was separated by column chromatography to give a desirable product( 45mg<br>
Yield(%): 17.6 m.p: 170-171°C<br>
!H NMR(CDC13):   S  1.02(3H,t,J=7.5Hz), 2.09(2H,br), 2.15(2H,br), 2.68(2H,<br>
q,J=7.5Hz),	3.64(4H,U=7.5Hz),	4.62(2H,s),<br>
5.20(lH,s), 7.16(2H,dJ=7.5Hz), 8.40(lH,s).<br>
Example 25)<br>
l-{[4-Bis(hydroxymethyl)cyclopent-l-en-l-yl]methyl}-5~ethyl-6-(3,5-<br>
dimethyl-phenylthio)-2,4-pyrimidinedione.<br>
5-Ethyl-6-(3,5-dimethylphenylthio)-2,4-pyrimidinedione	and<br>
[4~bi s (t-butyldimethy IsilyloxymethyDcyclopent- 1 -en-1 -yljmethyl bromide were reacted by the same method with example 24 to obtain the titled compound ( 48mg ).<br>
Yield(%): 17.5<br>
m.p: 156-157°C<br><br>
H<br><br>
: 3 1.02(3H,t,J=7.4Hz), 2.08(2H,s), 2.14(2H,s), 2.28(6H,s), 2.68(2H,q,J=7.5Hz), 3.62(4H,tJ=11.2Hz), 4.62(2H,s), 5.21(lH,s), 6.75(lH,s), 6.88(lH,s), 9.61(lH,s).<br><br>
Mass: m/e 416(M+), 91(100)<br>
Example 26)<br><br>
l-{[4-Bis(hydroxymethyl)cyclopent-l-en-l-yl]methyl}-5-isopropyl-6-phenylthio-2,4-pyrimidinedione.<br>
5-Isopropyl-6-phenylthio-2,4-pyrimidinedione	and<br>
[4-bis(t-butyldimethylsilyl	oxymethyl)cyclopent-l-en-l-yl]methyl<br>
bromide were reacted by the same method with example 24 to obtain the titled compound( 52mg ).<br>
Yield(%): 19.6 m.p: 148-149°C<br>
'l-I    NMR(CDC13):     8     1.19(3H,s),    1.20(3H,s),    2.06(2H,s),    2.17(2H,s),<br>
3.45-3.51 (lH,m), 3.59(4H, tJ=11.0Hz), 4.69(2H,s), 5.21 (lH,s), 7.16(2H,dJ=7.5Hz), 7.25(lH,tJ=7.5Hz), 7.33(2H,t,J=7.5Hz), 9.55(lH,s).<br>
Example 27)<br>
l-{[4-Bis(hydroxymethyl)cycloi3ent-l-en-l-yl]methyl}-5-isopropyl-6-(3,<br>
5-dimethylphenylthio)-2,4-pyrimidinedione.<br>
5-Isopropyl-6- (3,5-dimethylphenylthio) -2,4-pyrimidinedione	and<br>
[4-bis(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl bromide were reacted by the same method with example 24 to obtain the titled compound( 44mg ).<br>
Yielcl(%): 15.5 m.p: 156-157°C<br>
*H    NMR(CDC13):     8     1.02(3H,s),	1.21(3H,s),    2.08(2H,s),	2.16(2H,s),<br>
2.28(6H,s),         3.45-3.51 (lH,m),	3.62(4H,s),<br>
4.68(2H,s),	5.21(lH,s),      6.76(lH,s),	6.87(lH,s),<br>
6.69(lH,s).<br>
Example 28)<br><br>
l-f[3,4-Di(hydroxymethyl)cycloijent-l-en-l-yl]methyl}-5-ethyl-6-phenyl -thio-2,4-pyrimidinedione<br>
28-a)<br>
[3,4-Di(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl bromide<br>
A mixture of carbon tetrabromideC 3.18g, 9.6mmol ) and triphenyl phosphine( 3.15g, 12.9mmol ) were added to [3,4-di(t-butyldimethylsilyl oxymethyl)cyclopent-l-en-l-yl]methyl alcohoK 3.09g, S.Ommol ) in dichloromethane under ice bath and then, the reaction mixture was stirred for 30min at 0°C. After overnight at room temperature, the reaction mixture was extracted with dichloromethane, dried with MgS04, filtered, concentrated and separated by column chromatography to give a desirable product(2.43g).<br>
Yield(%): 67.4<br>
'H    NMlKCDCla):     3         0.05(6H,s),    0.91(9H,s),    1.85(lH,dJ=15.5Hz),<br>
2.26(2H,m),	2.62-2.70(3H,m),<br>
3.44(lH,t,J=9.0Hz),	3.60(2H,m),<br>
3.78(lH,dJ=7.5Hz), 4.08(2H,s), 5.25(lH,s).<br>
28-b)<br>
l-[3,4-Di(hydroxymethylcyclopent-l-en-l-yl)methyl]-5-ethyl-6-phenyl-thio-2,4-pyrimidinedione<br>
A   mixture   of   5-ethyl-6-phenylthio-2,4-pyrimidinedione(   0.16g,<br>
O.GGmmol	)	and<br>
[3,4-di(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl<br>
bromide( 0.30g, 0.66mmol ) in dimethylformamide( 10ml ) were heated<br>
at 50°C for overnight in the presence of sodium bicarbonate(  66mg,<br>
0.79mmol     ).	After    the    concentration     of     dimethylformamide,<br>
l-{[3,4-di(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl}-5-ethyl-G-phenylthio-2,4-pyrimidinedione was obtained by the separation of the column chromatography.       And then, this compound in    THF(<br><br>
10ml ) was reacted with n-tetrabutylammonium fluoride at room temperature for Ihr. After the concentration of THF, the residue was separated by column chromatography to give a desirable product(<br>
Yield(%): 18.7<br>
'II    NMR(CDCb):         S     l.Q3(3H,t),    1.84(lH,dJ=15.5Hz),    2.38(2H,m),<br>
2.60(lH,br)	2.70(2H,qJ=7.0Hz),<br>
3.44(lH,tJ=9.0Hz),	3.59-3.63(2H,m),<br>
3.78(lH,dJ=7.5Hz), 4.59(2H,dd, J=4.5, 7.0Hz), 5.25(lH,s), 7.16(lH,d, J=7.5Hz), 7.26(lH,t, J=8.5Hz), 7,34(2H,t, J=7.5 Hz), 9.30(lH,s).<br>
Example 29)<br>
l-{[3,4-Di(hydroxymethyl)cyclopent-l-en-l-yl]methyl}-5-ethyl-6-(3,5-di<br>
-methylphenylthio)-2,4-pyrimidinedione<br>
5-Ethyl~6-(3,5-dimethylphenylthio)-2,4-pyrimidinedione	and<br>
[3,4-di(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl bromide were reacted by the same method with example 28 to obtain the titled compound( 53mg ).<br>
(%): 19.3 m.p: 156-157°C<br>
'H NMRCCDCb):   §   1.03(3H,tJ=7.5Hz),  1.86(lH,d,J-15.5Hz),  2.28(6H,s),<br>
2.42(2H,m),	2.60(lH,m),	2.68-2.73(2H,m),<br>
3.44(lH,t,J=7.5Hz),	3.56-3.64(2H,m),<br>
3.79(lH,dJ=7.5Hz),   4.59(2H,dJ=8.5Hz),   5.27(lH,s), 6.76(2H,s), 6.88(lH,s), 9.44(lH,s).<br>
Example 30)<br>
l-{[3,4-Di(hydroxymethyl)cyclopent-l-en-l-yl]methyl}-5-isopropyl-6-(3,<br>
5-dimethylphenylthio)-2,4-pyrimidinedione<br><br>
5-Isopropyl-6-(3,5-dimethylphenylthio)-2,4-pyrimidinedione and [3,4-di<br>
(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl	bromide<br>
were reacted by the same method with example 28 to obtain the titled compound( 51mg ).<br>
Yield(%): 17.9<br>
m.p: 136-137°C<br><br>
NMR(CDC13):<br><br>
1.20(3H,dJ=7.0Hz), 1.25(3H,dJ=7.0Hz),<br>
1.87(lH,dJ=15.5Hz),	2.28(6H,s),<br>
2.40-2.44(2H,m),	2.60(lH,br),<br>
2.96-3.00(lH,m),	3.44-3.53(2H,m),<br>
3.58-3.65(lH,m), 3.80(1H, ddj=4.0, 6.5Hz), 4.62-4.69(2H,m), 5.27(lH,s), 6.76(2H,s), 6.88(lH,s), 9.01 (lH,s).<br><br>
Example 31)<br>
l-{[3,4-Di(hydroxymethyl)cycloi3ent-l-en-l-yl]methyl}-5-ethyl-6-(3,5-di<br>
-melhylphenoxy)-2,4-pyrimidinedione<br>
5-Ethyl-6-(3,5-dimethylphenoxy)-2,4-pyrimidinedione	and<br>
[3,4-di(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl bromide were reacted by the same method with example 28 to obtain the titled compound( 42mg ).<br>
Yield(%): 17.9<br>
'H   NMR(CDC13):    3    0.94(3H,t),   1.82(lH,dJ=15.5Hz),   2.18-2.22(2H,m),<br>
2.31 (6H,s),	2.38-2.45(2H,m),       2.76(lH,br),<br>
3.42-3.49(2H,m),      3.60(lH,m),	3.94(lH,m),<br>
4.33(2H,ddJ=15.5,  29.5Hz), 5.43(lH,s),  6.52(2H,s), 6.78(lH,s), 9.79(lH,s).<br>
Example 32)<br><br>
l-{[3,4-Di(hydroxymethyl)cycloi3ent-l-en-l-yl]methyl}-5-isopropyl-6-(3, 5-dimethylphenoxy)-2,4-pyrimidinedione<br>
5-Iso]jropyl-6-(3,5-dimethylphenoxy)-2,4-pyrimidinedione	and<br>
[3,4-di(t-	butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl<br>
bromide were reacted by the same method with example 28 to obtain the titled compound( 48mg ).<br>
Yield(%): 17.5<br><br>
NMR(CDC13):<br><br>
1.21(3H,dJ=7.0Hz),        1.24(3H,dJ=7.0Hz),<br>
1.83(lH,dJ=15.5Hz),	2.31 (6H,s),<br>
2.37(2h,m),   2.57(lH,br),   2.74-2.79(lH,m),<br>
3.38-3.50(2H,m),	3.60(lH,qJ=5.0Hz),<br>
3.90(lH,dJ=7.0Hz), 4.25(1H,   dJ=16.0Hz),<br>
4.34(lH,dJ=16.0Hz),	5.42(lH,s),<br>
6.51 (2H,s), 6.77(lH,s), 9.33(lH,s).<br><br>
Example 33)<br>
l-{[3,4-Di(hydroxymethyl)cyclopent-l-en-l-yl]methyl}-5-ethyl-6-(3,5-di<br>
-methylbenzoyl)-2,4-pyrimidinedione<br>
5-Ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
[3,4-di(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl bromide were reacted by the same method with example 28 to obtain the titled compound( 68mg ).<br>
Yield(%): 25.0<br>
m.p: 79-80"C<br><br>
NMR(CDCls):<br><br>
0.94-0.97(3H,tJ=7.5Hz). 1.54(lH,dJ=15.5Hz),<br>
2.03-2.04(lH,m), 2.31-2.35(5H,m), 2.39(3H,s),<br>
2.40(3H,s), 3.27-3.33(lH,m), 3.41 (lH,m),<br>
3.50(lH,m),	3.79(lH,m),	4.3<br><br>
440(lH,d),	5.34(lH,m),<br>
7.49(2H,s), 9.06(lH,s).<br><br>
7.31 (lH,s),<br><br>
Example 34)<br>
l-{[3,4-Di(hydroxymethyl)cycloi3ent-l-en-l-yl]methyl}-5-isopropyl-6-(3,<br>
5-dimethylbenzoyl)-2,4-pyrimidinedione<br>
5-Isopropyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
[3,4-di(t-butyldimethylsilyloxymethyl)cyclopent-l-en-l-yl]methyl bromide were reacted by the same method with example 28 to obtain the titled compound( 74mg ).<br>
Yield(%): 26.3<br>
m.p: 81-82°C<br><br>
1H       NMR(CDC13):<br><br>
8        1.20(3H,dJ=7.0Hz),        1.24(3H,dJ=7.0Hz),<br>
1.50(lH,dJ=15.5Hz),	2.24-2.31 (2H.m),<br>
2.39(3h,s), 2.40(3H,s), 2.54(2H,m),<br>
3.29(lH,m), 3.40QH, br), 3.49(lH,m),<br>
3.71-3.84(lH,m),	4.27-4.39(lH,m),<br>
5.20-5.34(lH,m), 7.33(lH,s), 7.49(2H,s), 9.39(lH,s).<br><br>
Ezamijle 35)<br>
l-[2-(Cyclopent-l-en-l-yl)ethyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-<br>
pyrimidinedione<br>
35-a) 2-(Cyclopent-l-en-yl)ethyl toluenesulfonate<br>
A para-toluenesulfonylchloride( 3.81g, 20mmol ) was added to the pyricline( 30ml ) solution of 2-(cyclopent-l-en-l-yl)ethyl alcohoK 2.24g, 20mmol ) and then the reaction mixture was stirred at room temperature for 2hrs. After the removement of pyridine, the residue was extracted with dichloromethane, washed with IN HC1, dried, filtered and separated by column chromatography to give a desirable<br><br>
product ( 2.80g ). Yield(%): 52.6<br>
'li NMR(CDCla):   8  0.82(2H,m), 1.99-2.30(6H,m), 2.49(3H,s), 3.<br>
4.03(lII,m), 5.22(lH,s), 7.41(2H,d), 7.74(2H,d).<br>
35-b)<br>
l-[2-(Cyclopent-l-en-l-yl)ethyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione<br>
A mixture of sodium bicarbonate( O.lOg, 1.2mmol ) and lithium iodide( 13mg, O.lmmol ) were added to dimethylformamide solution( 10ml ) of 5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione( 0.27g, l.Ommol ) and 2-(cyclopent-l-en-l-yl)ethyl toluenesulfonate( 0.27g, l.Ommol ). And then, the reaction mixture was stirred at 90°C for overnight, concentrated for removement of dimethylformamide, extracted with dichloromethane, dried, filtered and separated by column chromatography to give a desirable product as a white solid ( 148mg ).<br>
Yield(%): 40.4 m.p: 211-213°C<br>
*H      NMR(CDCk):       3       0.81(2H,dd,J=7.0,1.5Hz),      0.97(3H,t,J=7.5Hz),<br>
1.99-2.30(6H,m),      2.40(6H,s),      3.29(lH,m),<br>
3.91 (lH,m),	5.22(lH,s),	7.35(lH,s),<br>
7.50(2H,s), 8.81 (lH,s).<br>
Mass: m/e 366(M+), 94(100)<br>
Example 36)<br>
l-[2-(Cyclopent-3-en-l-yl)ethyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-<br>
pyrimidinedione<br>
36-a) 2-(Cyclopent-3-en-l-yl)ethyl toluenesulfonate<br><br>
A para-toluenesulfonylchloride( 3.81 g, 20mmol ) was added to the pyridine( 30ml ) solution of 2-(cyclopent-3-en-l-yl)ethyl alcohoK 2.24g, 20mmol ) and then the reaction mixture was stirred at room temperature for 2hrs. After the removement of pyridine, the residue was extracted with dichloromethane, washed with IN HC1, dried, filtered and separated by column chromatography to give a desirable product ( 3.24g ).<br>
Yield(%): 60.8<br><br>
NMRCCDCk):    8<br><br>
1.69(2H,m), 1.85(2H,m), 2.02(2H,m), 2.25(lH,m), 3.42(lH,m), 3.94(lH,m), 5.56(2H,d), 7.4192H,d), 7.74(2H,d).<br><br>
36-b)<br>
l-[2-(Cyclopent-3-en-lyl)ethyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione<br>
A mixture of sodium bicarbonate( O.lOg, 1.2mmol ) and lithium iodide ( 13mg, O.lmmol ) were added to dime thy Iformamide solution ( 10ml ) of 5-ethyl-6- (3,5-dimethylbenzoyl) -2,4-pyrimidinedione( 0.27g, l.Ommol ) and 2-(cyclopent-3-en-l-yl)ethyl toluenesulfonate( 0.27g, l.Ommol ). And then, the reaction mixture was stirred at 90°C for overnight, concentrated for removement of ctimethylformamide, extracted with dichloromethane, dried, filtered and separated by column chromatography to give a desirable product as a white solid ( 136mg ).<br>
Yield(%): 37.1<br><br>
m.p: 190-191°C *H   NMR(CDCls):<br><br>
0.97(3H,tJ=7.5Hz),    1.69(2H,m),    1.85(2H,m),<br>
2.02(2H,m),	2.25(lH,m),    2.37(3H,m),<br>
2.41 (6H,s),      3.17(lH,m),       3.82(1H,       m), 5.56(2H,d), 7.36(lH,s), 7.53(2H,s), 8.64(lH,s).<br><br>
Mass: m/e 366(M+), 94(100)<br>
Example 37)<br>
l-[2-(Cyclopent-3-en-l-yl)ethyl]-5-isopropyl-6-(3,5-dimethylbenzoyl)-2, 4 -py rimidinedione<br>
5-Isopropyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
2-(cyclopent-   3-en-l-yl)ethyl   toluenesulfonate   were   reacted   by   the same method with example 35 to obtain the titled compound(140mg).<br>
Yield(%): 36.8 m.p: 175-176°C<br>
*H NMR(CDC13):     S   1.13(3H,d,J=7.0Hz), 1.20(3H,d,J=7.0Hz), 1.70(2H,m),<br>
1.82(2H,m), 2.03(lH,m), 2.33(3H,m), 2.41(6H,s), 3.13(lH,m), 3.80(lH,m), 5.56(2H,ddJ=40,10.0Hz), 7.36(lH,s), 7.55(2H,s), 8.45(lH,s).<br>
Example 38)<br>
l-[2-(Cyclopent-3-en-l-yl)ethyl]-5-isopropyl-6-(3,5-dimethylphenoxy)-<br>
2,4-pyrimidinedione<br>
5-Isopropyl-6- (3,5-dimethyl2phenoxy )-2,4-pyrimidinedione	and<br>
2-(cyclopent-   3-en~l-yl)ethyl   toluenesulfonate   were   reacted   by   the same method with example 35 to obtain the titled compound(109mg).<br>
Yield(%): 29.6 m.p: 109-110°C<br>
*H     NMR(CDCla):      S     1.14(6H,dJ=7.0Hz),     1.70(2H,m),     1.93(2H,m),<br>
2.15(lH,m),	2.31 (6H,s),        2.45(2H,m),<br>
2.79(lH,m),      3.67(2H,t,J=7.5Hz),      5.62(2H,s),<br><br>
6.53(2H,s), 6.78(lH,s), 8.83(lH,s).<br>
Example 39)<br>
l-[2-(Cyclopent-3-en-l-yl)ethyl]-5-isopropyl-6-(3,5-dimethylphenylthio)<br>
-2,4-pyrimidinedione<br>
5-Isopropyl-6- (3,5-dimethylphenylthio) -2,4-pyrimidinedione	and<br>
2-(cyclopent 3-en-l-yl)ethyl toluenesulfonate were reacted by the same method with example 35 to obtain the titled compound (134mg).<br>
(%): 34.8 m.p: 128-129T<br>
]H    NMR(CDCls):         8     1.24(6H,dJ=7.0Hz),    1.68(2H,m),	2.03(2H,m),<br>
2.18(lH,m),	2.29(6H,s),	2.48(2H,m),<br>
3.53(lH,m),     4.00(2H,tJ=8.0Hz),	5.64(2H,s),<br>
6.77(2H,s), 6,88(lH,s), 8.95(lH,s).<br>
Mass: m/e 384(M+), 247(100)<br>
Example 40)<br>
l-{2-(Cyclopent-2-en-l-yl)ethyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-<br>
pyrimidinedione<br>
40~a) 2-(Cyclopent-2-en-l-yl)ethyl bromide<br>
A mixture of carbon tetrabromide( 19.2g, 57.8mmol ) and triphenyl<br>
phosphine(	15.2g,          57.8mmol          )	were          added         to<br>
2-(cyclopent-2-en-l-yl)ethyl alcohoK 4.32g, 38.5mmol ) in dichloromethane( 15ml ) under ice bath and then, the reaction mixture was stirred for 2hrs at 0°C The reaction mixture was extracted with dichloromethane, dried with MgSO4, filtered, concentrated and separated by column chromatography to give a desirable product(5.53g).<br>
Yield(%): 82.0<br><br>
*H NMRCCDCls):  8  1.26-2.29(6H,m), 2.80(lH,m), 3.43(2H,t), 5.72(2H,s).<br>
40-b)<br>
l-[2-(Cyclopent-2-en-l-yl)ethyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione<br>
A mixture of sodium bicarbonate( O.lOg, 1.2mmol ) and lithium iodide( 13mg, O.lmmol ) were added to dimethylformamide solution( 10ml ) of 5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione( 0.27g, l.Ommol ) and 2~(cyclopent-2-en-yl))ethyl bromide( 0.18g, l.Ommol ). And then, the reaction mixture was stirred at 90°C for overnight, concentrated for removement of dimethylformamide, extracted with dichloromethane, dried, filtered and separated by column chromatography to give a desirable product as a white solid ( 112mg ).<br>
Yield(%): 30.6 m.p: 183-185°C<br>
*H   NMR(CDC13):    S    0.97(3H,t),   1.24(lH,m),   1.49(lH,m),	1.70(2H,m),<br>
2.00(lH,m),    2,24(2H,m), 2.41(6H,s),	2.49(lH,m),<br>
3.23(lH,m),  3.81 (lH,m),  5.48(lH,m),	5.66(lH,m),<br>
7.35(lH,s), 7.52(2H,s), 8.73(lH,s).<br>
Example 41)<br>
l-[2-(Cyclopent-2-en-l-yl)ethyl]-5-isopropyl-6-(3,5-dimethylbenzoyl)-2,<br>
4-pyrimidinedione<br>
5-Isopropyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
2-(cyclopent-   2-en-l-yl)ethyl   bromide   were   reacted   by   the   same method with example 40 to obtain the titled compound ( 123mg ).<br>
Yield(%): 32.3<br>
:H  NMRCCDCla):    8   1.15(3H,d,J=6.85Hz),   1.23(3H,dJ=6.85),   1.29(lH,m),<br><br>
1.42(lH,m),    1.75(2H,m),	1.92(lH,m),	2.05(lH,m),<br>
2.29(2H,m),    2.45(6H,s),	2.52(lH,m),	3.35(lH,m),<br>
3.92(lH,m),    5.50(lH,m),	5.73(lH,m),	7.92(lH,s),<br>
7.48(2H,s), 8.85(lH,s).<br>
Example 42)<br>
l-[2-(Cyclopent-2-en-l-yl)ethyl]-5-isopropyl-6-(3,5-dimethylphenoxy)-<br>
2,4-pyrimidinedione<br>
5~Isopropyl-6- (3,5-dimethylphenoxy )-2,4-pyrimidinedione	and<br>
2-(cyclopent-   2-en-l-yl)ethyl   bromide   were   reacted   by   the   same method with example 40 to obtain the titled compound( 132mg ).<br>
Yield(%): 35.8 m.p: 148-149°C<br>
XH   NMR(CDC13):    3    1.15(6H,d),   1.36(lH,m),   1.55(lH,m),   1.70(lH,m),<br>
2.00(lH,m),	2.27(2H,m),	3.69(2H,m),<br>
5.56(lH,ddJ=2.Q5Hz),	5.71 (lH,ddJ=2.25Hz),<br>
6.54(2H,s), 6.78(lH,s), 8.37(lH,s).<br>
Example 43)<br>
l-[2-(Cyclopent-2-en-l-yl)ethyl]-5-isopropyl-6-(3,5-dimethylphenylthio)<br>
-2,4-pyrimidinedione<br>
5-Isopropyl-6-(3,5-dimethylphenylthio)-2,4~pyrimidinedione	and<br>
2-(cyclopent-   2-en-l-yl)ethyl   bromide   were   reacted   by   the   same method with example 40 to obtain the titled compound( 98mg ).<br>
Yield(%): 25,5 m.p: 138-140°C<br><br>
1H    NMR(CDC13):     d     1.25(6H,ddJ=1.85Hz),    1.45(lH,m),    1.57(lH,m),<br>
1.68(2H,m),  2.01 (lH,m),  2.29(6H,s),  2.35(lH,m),<br>
2.61 (lH,m),        3.53(lH,m),	4.02(2H,t),<br>
5.59(lH,ddJ=2.0Hz),	5.72(lH,ddJ=2.25Hz),<br>
6.77(2H,s), 6.88(lH,s), 8.67(lH,s).<br>
Example 44)<br>
l-(2-Cyclopentyl)ethyl-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidine-<br>
dione<br>
44-a) (2-Cyclopentyl)ethyl toluenesulfonate<br>
A para-toluenesulfonyl chloride( IG.Og, 83.8mmol ) was added to the pyridineC 250ml ) solution of (2-cyclopentyl)ethyl alcohol( 8.76g, 76.2mmol ) and then the reaction mixture was stirred at room temperature for 6hrs. After the removement of pyridine, the residue was extracted with ethyl acetate, washed with IN HC1, dried, filtered and separated by column chromatography to give a desirable product ( 15.7g ).<br>
Yield(%):73<br>
1H     NMR(CDC13):	8     0.90-1.89(llH,m),     2.45(3H,s),     4.05(2H,t),<br>
7.27-7.88(4H,dd).<br>
44-b)<br>
l-(2-Cyclopentyl)ethyl-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidine-one<br>
A mixture of sodium bicarbonate( O.lOg, 1.2mmol ) and lithium iodide( 13mg, O.lmmol ) were added to dimethylformamide solution( 10ml ) of 5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione( 0.27g, l.Ommol ) and 2-(cyclopentyl)ethyl toluenesulfonate( 0.27g, l.Ommol ). And then, the reaction mixture was stirred at 90°C for overnight, concentrated for removement of dimethylformamide, extracted with<br><br>
dichloromethane,      dried,      filtered      and      separated      by      column chromatography to give a white solid ( 90mg ).<br>
Yield(%): 24.5<br>
*H NMR(CDCl3):   8  0,95(2H,m), 0.97(3H,t), 1.41-1.62(9H,m), 2.02(lH,m),<br>
2.28(lH,m),     2.41 (6H,s),     3.18(lH,m),     3.79(lH,m), 7.35(lH,s), 7.52(2H,s), 8.64(lH,s).<br>
Example 45)<br>
l-(2-Cyclopentyl)ethyl-5-isopropyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimi-<br>
dinedione<br>
5-Isopropyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
(2-cyclopent-   yDethyl   toluenesulfonate   were   reacted   by   the   same method with example 44 to obtain the titled compound ( 95mg ).<br>
Yield(%): 24.9 m.p: 174-176°C<br>
*H NMR(CDC13):   8  0.95(2H,m), 1.15(3H,dJ=6.85Hz), 1.23(3H,dJ=6.85Hz),<br>
1.391.69(9H,m),   2.32(lH,m),   2.41(6H,s),  3.15(lH,m), 3.77(lH,m) 7.36(lH,s), 7.55(2H,s), 8.90(lH,s).<br>
Example 46)<br>
l-(2-Cyclopentyl)ethyl-5-isopropyl-6-(3,5-dimethylphenoxy)-2,4-pyriini-<br>
dinedione<br>
5-Isopropyl-6- (3,5-dimethylphenoxy )-2,4-pyrimidinedione	and<br>
(2-cyclopent-   yDethyl   toluenesulfonate   were   reacted   by   the   same method with example 44 to obtain the titled compound( 105mg ).<br>
Yield(%): 28.3 m.p: 136-138°C<br><br>
1H NMR(CDC13):   3   1.04(2H,m), 1.15(6H,d), 1.46-1.71(9H,m),  2.31 (6H,s)<br>
2.80(lH,m),     3.65(2H,t),     6.53(2H,s),     6.78(lH,s), 8.60(lH,s).<br>
Example 47)<br>
l-(2-Cyclopentyl)ethyl-5-isopropyl-6-(3,5-dimethylphenylthio)-2,4-pyri-<br>
midinedione<br>
5-Isopropyl-6-(3,5-dimethylphenoxy)-2,4-pyrimidinedione	and<br>
(2-cyclopent-   yDethyl   toluenesulfonate   were   reacted   by   the   same method with example 44 to obtain the titled compound( 80mg ).<br>
Yield(%): 20.7 m.p: 95-97°C<br>
:H NMR(CDC13):   8   1.11 (2H,m), 1.25(6H,d), 1.47-l,78(9H,m), 2.29(6H,s),<br>
3.53(lH,m),     4.00(2H,t),     6.77(2H,s),     6,.88(lH,s), 9.1991H,s).<br>
Example 48)<br>
l-[2-Bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-ethyl-6-phenylthio-<br>
2,4-pyrimidinedione<br>
A   sodium  bicarbonate(  O.lOg,   1.2mmol   )   was   added   to   a   stirred<br>
solution	of	dimethylformamide(	10ml	)	of<br>
5-ethyl-6-phenylthio-2,4-pyrimidinedione( 0.25g, l.Ommol ) and 2-bis(t-butyldimethylsilyloxymethyl)cyclopropane-l-yl]methyl bromide( 0.42g, l.Ommol ) and then, the reaction mixture was heated at 90°C for overnight. The reaction mixture was poured into water( 30ml ), extracted with ether ( 2 times ), dried, filtered, concentrated and separated by column chromatography to give l-[2-bis(t-butyldimethylsilyloxymethyl)cyclopropane-l-yl]methyl-5-ethyl -6-phenylthio-2,4-pyrimidinedione as a pale yellow oil( 125mg ). This compound in THF( 5ml ) was reacted with n-tetrabutylammonium<br><br>
fluoride( 1.0ml of l.Omol THF solvent ) at room temperature for 6hrs.<br>
The reaction mixture was concentrated for removement of THF and<br>
separated	by	column	chromatography	to	give<br>
l-[2-bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-ethyl-6-phenylthio-2,4-pyrimidinedione( 142mg ) as a white solid.<br>
Yield(%): 39.4 m.p:<br>
*H     NMR(CDC13):      8     0.22(lH,t,J=5.5Hz),     0.53(lH,ddJ=5.5,     3.5Hz),<br>
1.05(3H,t,J=7.0Hz),	1.07(lH,m),<br>
2.70-2.75(lH,m),	3.25(lH,dJ=11.0Hz),<br>
3.53(lH,d,J=13.0Hz),	3.75(lH,dJ=11.5Hz),<br>
4.05-4.13(2H,m),     4.20(lH,ddJ=4.0,      ll.OHz), 7.20(2H,d), 7.28(lH,t), 7.36(2H,t), 9.36   lH,s).<br>
Example 49)<br>
l-[2-Bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-ethyl-(3,5-dimethyl<br>
-phenylthio)-2,4-pyrimidinedione<br>
5-Ethyl-6-(3,5-dimethylphenylthio)-2,4-pyrimidinedione	and<br>
2-bis(t~butyl dimethylsilyloxymethyl)cyclopropane-l-yl]methyl bromide were reacted by the same method with example 48 to obtain the titled compound( 191 mg ).<br>
Yield(%): 49.0<br>
m.p:<br>
NMRCCDCla):    8       0.22(lH,tJ-5.0Hz),       0.53(lH,ddJ=8.5,   5.5Hz),<br>
1.04(3H,t,J=7.5Hz), 1.37-1.42(lH,m), 2.29(6H,s),<br>
2.71-2.74(2H,m),	3.28(lH,dJ=10.0Hz),<br>
3.53(lH,dJ=12.5Hz),	3.73(lH,dJ=11.0Hz),<br>
4.05-4.14(2H,m),	419(lH,dJ=11.5Hz),<br>
6.79(2H,s), 6.89(lH,s), 9.45(lH,s).<br><br>
Example 50)<br>
l-[2-Bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-ethyl-6-(3,5-dime-thy Iphenoxy) - 2,4-py rimidinedione<br>
5-Ethyl-6- (3,5-dimethylphenoxy )-2,4-pyrimidinedione	and<br>
2-bis(t-butyl dimethylsilyloxymethyl)cyclopropane-l-yljmethyl bromide were reacted by the same method with example 48 to obtain the titled compound( 151 mg ).<br>
Yield(%): 40.3<br>
*H   NMR(CDC13):    d        0.27(lH,tJ=5.5Hz),	0.59(lH,ddJ=5.0,   3.5Hz),<br>
0.94(3H,tJ=7.5Hz),	1.26(lH,m),<br>
2.17-2.24(2H,m),	2.32(6H,s),                  3.29<br>
lH,d,J=11.0Hz),	3.55(lH,dJ=12.5Hz),<br>
3.80(2H,dJ=H.OHz),	3.98(lH,dd,J=8.5, G.OHz),<br>
4.12(lH,dJ=12.5Hz)	6.79(2H,s),      6.80(lH,s),<br>
9.01(lH,s).<br>
Example 51)<br>
l-[2-Bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-ethyl-6-(3,5-dimeth ylbenzoyl)-2,4-pyrimidinedione<br>
5-Ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
2-bis(t~butyl dimethylsilyloxymethyl)cyclopropane-l-yl]methyl bromide were reacted by the same method with example 48 to obtain the titled compound( 202 mg ).<br>
Yield(%): 52.4 m.p: 79.5-80.4°C<br>
!H    NMR(CDCls):     8    0.10(lH,tJ=5.5Hz),        0.61(lH,ddJ-9.0,    5.5Hz),<br>
0.98(3H,tJ-7.0Hz),       1.21(lH,m),       2.26(2H,m),<br><br>
2.41 (6H,s),	3.35(lH,dJ=11.0Hz),<br>
3.45(lH,dJ=12.0Hz),	3.70-3.81 (2H,m),<br>
4.01-4.13(2H,m),	7.36(lH,s),	7.52(lH,s),<br>
7.59(lH,s), 8.97(lH,s).<br>
Example 52)<br>
l-[2-Bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-isopropyl-6-phenyl<br>
-thio-2,4-pyrimidinedione<br>
5-Isopropyl-6-phenylthio-2,4-pyrimidinedione	and<br>
2-bis(t-butyldimethyl silyloxy methyl )cyclopropane-l -yl] methyl bromide were reacted by the same method with example 48 to obtain the titled compound ( 106 mg ).<br>
Yield(%): 42.5<br><br>
NMR(CDC13):<br><br>
0.24(lH,tJ=5.5Hz),       0.55(lH,ddJ=8.0,   5.5Hz),<br>
1.12(lH,m),	1.20(3H,t,J=7.0Hz),<br>
1.26(3H,U=7.0Hz),	2.75-2.81 (lH,m),<br>
3.21(lH,dJ=H.OHz),	3.56(lH,dJ=12.0Hz),<br>
3.84(lH,dJ=H.O	Hz),       4.11-4.14(2H,m),<br>
4.25(lH,ddJ=4.0,     ll.OHz),     7.21 (2H,	d),<br>
7.29(lH,t), 7.36(2H,t), 8.26(lH,s).<br><br>
Example 53)<br>
l-[2-Bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-isopropyl-6-(3,5-<br>
dimethylphenylthio)-2,4-pyrirnidmedione<br>
5-Isopropyl-6- (3,5-dimethylphenylthio)-2,4-pyrimidinedione	and<br>
2-bis(t-butyl dimethylsilyloxymethyl)cyclopropane-l-yl]methyl bromide were reacted by the same method with example 48 to obtain the titled compound( 211mg ).<br>
Yield(%): 52.1<br>
m.p:<br><br>
0.24(lH,U=5.5Hz),<br>
1.10(lH,m)f<br>
1.26(3H,dJ=7.0Hz),<br>
.26(lH,dJ=11.0Hz),<br>
3.75(lH,dJ=H.OHz),<br>
4.25(lH,ddJ=4.0,<br>
6.89(lH,s), 9.00(lH,s).<br>
NMR(CDC13):    8<br><br>
0.55(lH,dd,J=8.0,   5.5Hz), 1.21(3H,dJ=7.0Hz), 2.75-2.81 (lH,m), 3.56(lH,dJ=12.0Hz), 4.11-4.13(2H,m), ll.OHz),        6.75(2H,s),<br><br>
Example 54)<br>
l-[2-Bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-isoi3ropyl-6-(3,5-dimethy Iphenoxy) - 2,4 -py rimidinedione<br>
5-Isopropyl-6- (3,5-dimethylphenoxy )-2,4-pyrimidinedione	and<br>
[2-bis(t~butyl dimethylsilyloxymethyl)cyclopropane-l-yl]methyl bromide were reacted by the same method with example 48 to obtain the titled compound ( 168 mg ).<br>
Yield(%): 43.2<br>
m.p: 90.8-91.6°C<br><br>
NMR(CDC13):      S<br><br>
0.24(lH,U=5.5Hz),     0.58(lH,ddJ=5.0,     3.5Hz),<br>
1.12(3H,dJ=7.0Hz),	1.15(3H,d,J=7.0Hz),<br>
1.20-1.22(lH,m),	2.32(6H,s),<br>
2.75-2.81 (lH,m),	3.28(lH,dJ=H.OHz),<br>
3.54(lH,dJ=12.0Hz),	3.75-3.79(2H,m),<br>
3.94(lH,ddJ=8.5, G.OHz), 4.10(lH,d,J=12.0   Hz), 6.57(2H,s), 6.79(lH,s), 8.70(lH,s).<br><br>
Example 55)<br>
l-[2-Bis(hydroxymethyl)cyclopropane-l-yl]methyl-5-isopropyl-6-(3,5-<br>
dimethylbenzoyl)-2,4-pyrimidinedione<br>
5-Isopropyl-6- (3,5-dimethylbenzoyl)-2,4-pyrimidinedione	and<br>
[2-bis(t-butyl  dimethylsilyloxymethyl)cyclopropane-l-yljmethyl bromide<br><br>
were reacted by the same method with example 48 to obtain the titled compound ( 194 mg ).<br>
Yield(%): 48.5<br>
m.p: 91-92°C<br><br>
TH     NMlKCDCh):      d<br><br>
0.07(lH,t,J=5.5Hz),    0.60(lH,dd,J=9.0,    S.OHz),<br>
1.13(3H,t,J=6.5Hz),	1.23(3H,dJ=8.0Hz),<br>
1.25(lH,m),    2.33-2.35(lH,m),    2.41        (6H,s),<br>
3.28(lH,d,J=12.0Hz),	3.35(lH,d,J=12.5Hz),<br>
3.68-3.77(2H,m),   3.96-4.12(2H,m),   7.36(lH,s), 7.54(lH,s), 7.60(lH,s),     8.84(lH,s).<br><br>
Experimental Example<br>
Antiviral activity and Toxicity test<br>
The anti-HIV assays were based on the inhibition of the virus-induced cytopathic effect in MT-4 cells as a described method in J. Med. Chem, 34, 357, 1991. Briefly, MT-4 cells were suspended in culture medium at 2.5x105 cells/ml and infected with 1000 CCIDso ( 50% cell culture infective dose ) of HIV. Immediately, after virus infection, 100/^ of the cell suspension was brought into each well of a flat-bottomed microtitray containing various concentrations of the test compounds. After a 4 or 5 days incubation at 37°C, the number of viable cells was determined by the 3-(4, 5-dimethylthiazol-2-yl)-2 , 5-diphenyltetrazolium bromide (MTT) method, as disclosed in J . Virol . Methods, 20, 309, 1988. The cytotoxicity of the compounds of the present invention was assessed in parallel with their antiviral activity. It was based on the viability of mock-infected host cells as determined<br><br><br>
Table Removed<br><br>
It   was   found   that   the   compounds   of   present   invention   have   the superior antiviral activities to this control, AZT. Example of pharmaceutical preparations<br>
Injectable   preparations   were   prepared   with   the	ingredients   of  the<br>
following tables by the conventional injection manufacturing method.<br>
ingredients	the amount used<br>
ampul ( 5ml )                  compound of example 4	lOmg<br>
polyoxy40hydrogenated	2mg<br>
caster oil<br>
lidocaine • HC1	5mg<br>
anhydrous citric acid	O.Smg<br>
sodium citrate	0.1 mg<br>
sodium chloride	q.s<br>
ethanol	1ml<br>
distillation water for injection	q.s<br>
Vials were prepared with the ingredients of the	following tables by<br>
the conventional   manufacturing method.<br>
Vials( 150mg )                  compound of example 4	lOOmg<br>
methylparaben	LOmg<br>
propylparaben	0.5mg<br>
anhydrous citric acid	30mg<br>
sodium citrate	18.5mg<br>
Tablets were prepared with the ingredients of the	following tables by<br>
the conventional   manufacturing method.<br>
tablet( 700mg )                 compound of example 4	250mg<br>
corn starch	130mg<br>
microcrystalline cellulose	50mg<br>
lactose monohydrate	180mg<br>
hydroxypropyl cellulose	30mg<br><br>
polyvinylpyroridone k~30	30mg<br>
magnesium stearate	lOmg<br>
carboxymethylcellulose calcium	20mg<br>
Capsules were prepared with the ingredients of the following tables by the conventional   manufacturing method.<br>
capsule ( 400mg )             compound of example 4	250mg<br>
lactose monohydrate	lOOmg<br>
starch	35mg<br>
hydroxypropylcellulose	5mg<br>
magnesium stearate	lOmg<br><br><br>
We Claim:<br>
1.   The pyrimidinedione homocarbocyclic compound of general Formula (I) and pharmaceutically acceptable salts formed with inorganic or organic acids<br><br>
(Formula Removed)<br>
Wherein R1, R2 and R3 represents independently hydrogen atom, halogen atom,C1-C10 alkyl, C1-C10 thioalkyl C3-C4 optionally substituted cyclic alkyl, unsaturated alkyl, substituted alkyl hydroxyl, aryl hydroxyl, C1-C10alkylamine, nitro, C1-C4 lower ester,C1-C4lower alkoxy, C1-C4 lower thioalkoxy; Z represents oxygen atom, sulfur atom, carbon atom and carbonyl group; X represents oxygen  atom, sulfur atom; n represents an integer of 1-3; and (sub) cycloalk(en)yl represents<br>
(Formula Removed)<br>
in which    <br>
(Formula Removed)<br>
represents<br>
(Formula Removed)<br><br>
in which R4 and R5 represents independently hydrogen atom, hydroxymethyl, protected hydroxymethyl, benzyl, substituted carbonyl, substituted alkylsulfonyl or arylsulfonyl, substituted silyl or the like.<br>
2. A pyrimidinedione homocarbocyclic compound as claimed in claim 1, as and when used to prepare a pharmaceutical composition comprising the compound of formula (I) or acid addition salt thereof as active ingredient and one or more conventional adjuvants.<br>
3.The pyrimidinedione homocarbocyclic compound of general formula (I) and pharmaceutically acceptable salt of inorganic or organic acid thereof, substantially as hereinbefore described with reference to the foregoing examples.<br><br><br><br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUFic3RyYWN0LSgwMy0wMy0yMDA4KS5wZGY=" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Abstract-(03-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">412-del-1997-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUNsYWltcy0oMDMtMDMtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Claims-(03-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUNsYWltcy0oMDYtMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Claims-(06-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">412-del-1997-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMDMtMDMtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Correspondence-Others-(03-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMDYtMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Correspondence-Others-(06-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">412-del-1997-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LURlc2NyaXB0aW9uIChDb21wbGV0ZSktKDAzLTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Description (Complete)-(03-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LURlc2NyaXB0aW9uIChDb21wbGV0ZSktMDYtMDgtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Description (Complete)-06-08-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">412-del-1997-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUZvcm0tMS0oMDMtMDMtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Form-1-(03-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">412-del-1997-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">412-del-1997-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUZvcm0tMi0oMDMtMDMtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Form-2-(03-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">412-del-1997-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUZvcm0tMy0oMDMtMDMtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Form-3-(03-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LUZvcm0tMy0oMDYtMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Form-3-(06-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWZvcm0tNC5wZGY=" target="_blank" style="word-wrap:break-word;">412-del-1997-form-4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWZvcm0tNi5wZGY=" target="_blank" style="word-wrap:break-word;">412-del-1997-form-6.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLWRlbC0xOTk3LWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">412-del-1997-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDEyLURFTC0xOTk3LVBldGl0aW9uLTEzNy0oMDYtMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">412-DEL-1997-Petition-137-(06-08-2008).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="222436-novel-aryl-and-heteroaryl-propene-amide-thioamide-compounds.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="222438-fuel-conversion-reactor.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>222437</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>412/DEL/1997</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>36/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>05-Sep-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>08-Aug-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>20-Feb-1997</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SAMJIN PHARMACEUTICAL CO., LTD,</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>338-8,SEOKYO-DONG, MAPO-KU, SEOUL 121-210 REPUBLIC OF KOREA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>CHO, EUI-HWAN</td>
											<td>105-101, HYUNDAI 1ST APT, KAEPO-DONG KANGNAM,-KU, SEOUL, 135-240 , REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>CHUNG, SUN-GAN</td>
											<td>131-904, MOKHWA, APT, 850 KEUMJEONG-DONG, KUNPO, KYUNGKI-DO, 435-050, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>3</td>
											<td>KIM, JOONG-YOUNG</td>
											<td>6-1108, SAMSUNG 1ST APT, MAERTON, 4-DONG, PALDAL-KU, SUWEON, KYUNGKID-442-374, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>4</td>
											<td>KWON HO-SEOK</td>
											<td>506-1105, SINDONGA APT, 1274, SWONSUN-DONG, KWONSUN-KU, SUWEON, KYUNGKI-DO, 441-390, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>5</td>
											<td>LEE SUN-HWAN</td>
											<td>105-403 DAELIM APT, DOKKOK-DONG, SONGTAN, KYUNGKI-DO, 459-100, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>6</td>
											<td>LEE JAE-EUNG</td>
											<td>390-3, SINJANG-DONG, HANAM, KYUNGKI, DO ,465-032, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>7</td>
											<td>JOO JEONG-HO</td>
											<td>289-83, NORYANGJIN 2-DONG, DONGJAK-KU, SEOUL 156-052, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>8</td>
											<td>KIM, BYUNG-CHUL</td>
											<td>102-412, AJOO 1ST APT JISAN -DONG SONGTAN KYUNGKI-DO, 459-110, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>9</td>
											<td>KANG, DONG-WOOK</td>
											<td>268-203, JOOKONG APT, 4 WONMOON-DONG, KWACHON, KYUNGKI-DO ,427-030, REPUBLIC OF KOREA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/505</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>1996-4189</td>
									<td>1996-02-22</td>
								    <td>Republic of Korea</td>
								</tr>
								<tr>
									<td>2</td>
									<td>1996-47458</td>
									<td>1996-10-22</td>
								    <td>Republic of Korea</td>
								</tr>
								<tr>
									<td>3</td>
									<td>1996-25441</td>
									<td>1996-06-28</td>
								    <td>Republic of Korea</td>
								</tr>
								<tr>
									<td>4</td>
									<td>1996-47459</td>
									<td>1996-10-22</td>
								    <td>Republic of Korea</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/222437-a-pyrimidinedione-homocarbocyclic-compound by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 08:31:13 GMT -->
</html>
